• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why U.S. Stocks Are Trading Lower; Job Openings Drop To This Level In June

    8/2/22 10:34:43 AM ET
    $AMTD
    $DZSI
    $FATBB
    $LNFA
    Finance: Consumer Services
    Finance
    Telecommunications Equipment
    Utilities
    Get the next $AMTD alert in real time by email

    U.S. stocks traded lower this morning, with the Dow Jones falling more than 250 points on Tuesday.

    Following the market opening Tuesday, the Dow traded down 0.87% to 32,511.89 while the NASDAQ fell 0.47% to 12,311.33. The S&P also fell, dropping, 0.60% to 4,094.02.

    Also check this: Bitcoin Declines Below This Major Level, Here Are The Top Crypto Movers For Tuesday


    Leading and Lagging Sectors


    Health care shares climbed 0.5% on Tuesday. Meanwhile, top gainers in the sector included Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), up 28% and Nutex Health, Inc. (NASDAQ:NUTX) up 19%.


    In trading on Tuesday, information technology shares fell 1.1%.


    Top Headline


    The number of job openings dropped by 605,000 from a month ago to 10.7 million in June, the lowest in nine months. However, analysts were expecting a reading of 11 million.


    Equities Trading UP


    AMTD IDEA Group (NYSE:AMTD) shares shot up 298% to $8.28 after jumping 18% on Monday. The company owns 90%+ of AMTD Digital.


    Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) got a boost, shooting 28% to $16.02 as the company posted a narrower-than-expected Q2 loss.


    L&F Acquisition Corp. (NASDAQ:LNFA) shares were also up, gaining 26% to $13.45.


    Equities Trading DOWN

    Mobile Global Esports Inc. (NASDAQ:MGAM) shares tumbled 36% to $8.31 after jumping 16% on Monday.


    Shares of FAT Brands Inc. (NASDAQ:FATBB) were down 27% to $10.95. The company recently posted a Q2 net loss of $8.2 million or $0.50 per share.


    DZS Inc. (NASDAQ:DZSI) was down, falling 22% to $15.21 after the company reported worse-than-expected Q2 results.

    Also check out: Market Volatility Increases As U.S. Stocks Settle Lower After Recording Biggest Monthly Gains Since 2020


    Commodities

    In commodity news, oil traded up 0.2% to $94.06, while gold traded up 0.8% to $1,801.20.


    Silver traded down 0.2% to $20.325 on Tuesday while copper fell 0.9% to $3.5110.



    Euro zone


    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.4%, London’s FTSE 100 rose 0.1% while Spain’s IBEX 35 Index rose 0.2%. The German DAX slipped 0.3%, French CAC 40 fell 0.3% and Italy’s FTSE MIB Index fell 0.6%.

    The Nationwide House Price Index in the UK surged 11.0% year-over-year in July, higher than 10.7% in the previous month.


    Economics

     

    The number of job openings dropped by 605,000 from a month ago to 10.7 million in June, the lowest in nine months. However, analysts were expecting a reading of 11 million.


    Check out this: Fear Among US Investors Is Increasing, Here's Why


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 93,225,110 cases with around 1,055,570 deaths. India confirmed a total of at least 44,050,000 cases and 526,430 deaths, while France reported over 33,866,820 COVID-19 cases with 152,170 deaths. In total, there were at least 583,309,090 cases of COVID-19 worldwide with more than 6,422,510 deaths.

    Get the next $AMTD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMTD
    $DZSI
    $FATBB
    $LNFA

    CompanyDatePrice TargetRatingAnalyst
    Rhythm Pharmaceuticals Inc.
    $RYTM
    2/19/2026$478.00Outperform
    RBC Capital Mkts
    Rhythm Pharmaceuticals Inc.
    $RYTM
    11/25/2025$136.00Buy
    Citigroup
    Rhythm Pharmaceuticals Inc.
    $RYTM
    11/5/2025Outperform → Perform
    Oppenheimer
    Rhythm Pharmaceuticals Inc.
    $RYTM
    7/14/2025$130.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Rhythm Pharmaceuticals Inc.
    $RYTM
    7/10/2025$97.00Buy
    Goldman
    Rhythm Pharmaceuticals Inc.
    $RYTM
    7/7/2025$88.00Outperform
    Leerink Partners
    Rhythm Pharmaceuticals Inc.
    $RYTM
    4/7/2025$63.00Neutral → Buy
    BofA Securities
    Rhythm Pharmaceuticals Inc.
    $RYTM
    3/5/2025$78.00Buy
    Stifel
    More analyst ratings

    $AMTD
    $DZSI
    $FATBB
    $LNFA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

    -- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- BOSTON, March 01, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced additional positive data from its global Phase 3 TRANSCEND trial of setmelanotide in patients with acquired hypothalamic obesity (HO). This new data set inc

    3/1/26 12:30:00 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    With TGE Consolidated, AMTD Digital Reports Full Year Results with 565.7% Increase in Revenue, 132.7% Increase in Net Income, and 280.2% Increase in Net Assets

    PARIS and NEW YORK and LONDON, Feb. 27, 2026 /PRNewswire/ -- AMTD Digital Inc. ("AMTD Digital" or the "Company") (NYSE:HKD), a NYSE-listed company and a subsidiary of AMTD Group Inc., today announced the filing of its annual report on Form 20-F for the fiscal year ended October 31, 2025 with the Securities and Exchange Commission, which consolidates the financial results of The Generation Essentials Group (", TGE", , NYSE:TGE, LSE: TGE);  summary highlights below: Total Revenue increased by 565.7% from US$20.4 million to US$136.1 millionTotal Net Income increased by 132.7% from US$41.7 million to US$97.0 million Total Assets amounted to US$955.4 million (US$7.57/share)Net asset value amounte

    2/27/26 4:28:00 PM ET
    $AMTD
    $HKD
    $TGE
    Finance: Consumer Services
    Finance
    Newspapers/Magazines
    Consumer Discretionary

    AMTD IDEA's Subsidiary AMTD Digital Reports Full Year Results with 565.7% Increase in Revenue, 132.7% Increase in Net Income, and 280.2% Increase in Net Assets

    PARIS and NEW YORK and LONDON, Feb. 27, 2026 /PRNewswire/ -- AMTD IDEA (NYSE:AMTD, SGX: HKB)) subsidiary AMTD Digital Inc. (NYSE:HKD), a NYSE‑listed company and subsidiary of AMTD Group Inc., today announced it has filed its annual report on Form 20‑F with the U.S. Securities and Exchange Commission for the fiscal year ended October 31, 2025. Summary highlights are below: Total Revenue increased by 565.7% from US$20.4 million to US$136.1 millionTotal Net Income increased by 132.7% from US$41.7 million to US$97.0 million Total Assets amounted to US$955.4 million (US$7.57/share)Net asset value amounted to US$603.7 million (US$4.78/share)The annual report is available on AMTD Digital's investor

    2/27/26 4:27:00 PM ET
    $AMTD
    $HKD
    Finance: Consumer Services
    Finance

    $AMTD
    $DZSI
    $FATBB
    $LNFA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Smith Hunter C exercised 6,099 shares at a strike of $6.80, increasing direct ownership by 6% to 116,611 units (SEC Form 4)

    4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

    3/2/26 8:56:40 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Smith Hunter C sold $805,814 worth of shares (7,954 units at $101.31), decreasing direct ownership by 7% to 110,512 units (SEC Form 4)

    4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

    2/19/26 9:02:16 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Head of International Mazabraud Yann converted options into 10,000 shares, increasing direct ownership by 23% to 53,155 units (SEC Form 4)

    4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

    2/18/26 4:30:22 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTD
    $DZSI
    $FATBB
    $LNFA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Bates Jon Christian bought $102,532 worth of shares (750 units at $136.71), increasing direct ownership by 15% to 5,638 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    11/28/25 2:11:24 PM ET
    $NUTX
    Real Estate

    Director Elenowitz Mark bought $2,200 worth of Series B Cumulative Preferred Stock (1,000 units at $2.20), increasing direct ownership by 11% to 10,200 units (SEC Form 4)

    4 - Fat Brands, Inc (0001705012) (Issuer)

    6/3/25 7:45:58 PM ET
    $FATBB
    Restaurants
    Consumer Discretionary

    Chief Financial Officer Bates Jon Christian converted options into 1,611 shares and bought $81,810 worth of shares (1,000 units at $81.81), increasing direct ownership by 115% to 4,888 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    4/14/25 4:30:48 PM ET
    $NUTX
    Real Estate

    $AMTD
    $DZSI
    $FATBB
    $LNFA
    SEC Filings

    View All

    Rhythm Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

    3/2/26 6:01:48 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Rhythm Pharmaceuticals Inc.

    S-3ASR - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

    2/26/26 5:37:52 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Rhythm Pharmaceuticals Inc.

    S-8 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

    2/26/26 5:16:44 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTD
    $DZSI
    $FATBB
    $LNFA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Rhythm Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of Rhythm Pharmaceuticals with a rating of Outperform and set a new price target of $478.00

    2/19/26 7:52:12 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Rhythm Pharmaceuticals with a new price target

    Citigroup initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $136.00

    11/25/25 8:45:08 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals downgraded by Oppenheimer

    Oppenheimer downgraded Rhythm Pharmaceuticals from Outperform to Perform

    11/5/25 7:28:21 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTD
    $DZSI
    $FATBB
    $LNFA
    Leadership Updates

    Live Leadership Updates

    View All

    NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF WESLEY BAMBURG AS ITS NEW CHIEF OPERATING OFFICER

    HOUSTON, Sept. 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments  in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Wesley Bamburg as the Company's Chief Operating Officer, effective October 13, 2025. Mr. Bamburg is an accomplished healthcare executive with 20 years of Fortune 500 experience in healthcare operations, business development, integrated network management, and physician relations. Mr. Bamburg has served as Chief Operating Officer for HCA Houst

    9/22/25 6:30:00 AM ET
    $NUTX
    Real Estate

    NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF GRANT THORNTON LLP AS ITS INDEPENDENT AUDITOR

    HOUSTON, May 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm to replace CBIZ CPAs ("CBIZ"), effective May 15, 2025. The change of the Company's independent auditor was made after careful consideration and an evaluation process and was approved by the Audit Committee and the Board of Directors of the

    5/22/25 6:30:00 AM ET
    $NUTX
    Real Estate

    AMTD Appoints Global Editorial Leadership Team for The Art Newspaper

    AMTD Group and The Generation Essentials Group are pleased to announce the appointment of Julia Michalska as Global Editor-in-Chief of The Art Newspaper, the global art media company founded in 1990, with Benjamin Sutton taking the role of Editor-in-Chief, Americas. Both of them will become members of a global editorial committee formed to govern and monitor the global content and quality of The Art Newspaper. Since its inception 35 years ago, The Art Newspaper has developed into a multi-platform brand that has continuously maintained its reputation as the ‘journal of record' for the art world. Its distribution network includes a variety of print publications, a broad online presence, podc

    4/8/25 10:32:00 AM ET
    $AMTD
    $HKD
    Finance: Consumer Services
    Finance

    $AMTD
    $DZSI
    $FATBB
    $LNFA
    Financials

    Live finance-specific insights

    View All

    Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

    -- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) ---- Phase 2 open-label extension data showed bivamelagon achieved persistent BMI reductions at six and nine months; Completed positive end-of-Phase-2 meeting with FDA ---- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired HO in March 2026 -- -- On track to report topline data from Phase 3 EMANATE trial evaluating setmelanotide in rare genetically caused melanocortin-4 receptor (MC4R) pathway diseases in March 2026 -- -- Manag

    2/26/26 7:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call

    HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and

    2/25/26 5:29:00 PM ET
    $NUTX
    Real Estate

    Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

    BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Thursday, February 26, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. Also today, Rhythm announced that David Meeker, M.D., Chair, President and Chie

    2/17/26 8:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTD
    $DZSI
    $FATBB
    $LNFA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Rhythm Pharmaceuticals Inc.

    SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    11/14/24 9:50:26 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AMTD IDEA Group

    SC 13G/A - AMTD IDEA GROUP (0001769731) (Subject)

    11/14/24 9:37:44 PM ET
    $AMTD
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

    SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    11/14/24 5:46:11 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care